You are viewing an inactive listing
This listing is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active listings please search here

Clinical Trial 45239

NATIONWIDE


Summary:

Exicure Merkel Cell Carcinoma Research Study

The Merkel cell carcinoma research study will evaluate how safe and tolerable a new investigational treatment is both alone and in combination with pembrolizumab in adults who qualify. The research study is open label and non-randomized. This means that you will know information about the active ingredients in the investigational treatment.

Eligible study participants:

  • Are at least 18 years or older
  • Are diagnosed by a doctor with Merkel cell carcinoma and had your disease worsen on the standard treatments (pembrolizumab (Keytruda ®) or avelumab (Bavencio ®)) as the most recent treatment
  • Have tumors on or under your skin, or in lymph nodes
  • Do not have other cancers at the same time
  • Do not have active or documented history of an autoimmune disease or syndrome requiring steroid or immunosuppressive treatment

Additional study requirements and exclusions may apply. A study representative will discuss these with you during the screening period.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.